A novel application of E1A in combination therapy with EGFR-TKI treatment in breast cancer

Epidermal growth factor receptor (EGFR) is commonly overexpressed in breast cancer and is associated with poor clinical outcomes; however, an increasing number of patients have shown a poor effective response to EGFR tyrosine kinase inhibitors (EGFR-TKI). Here, we found that AXL expression was posit...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Chih-Ming, Chang, Ting-Yu, Hsu, Hui-Ping, Lai, Hui-Huang, Li, Jie-Ning, Lyu, Yu-Jhen, Kuo, Kuang-Tai, Huang, Ming-Te, Su, Jen-Liang, Chen, Pai-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325414/
https://www.ncbi.nlm.nih.gov/pubmed/27590506
http://dx.doi.org/10.18632/oncotarget.11737

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325414/
https://www.ncbi.nlm.nih.gov/pubmed/27590506
http://dx.doi.org/10.18632/oncotarget.11737

Ejemplares similares